Romark announced initial results from a phase 3 trial evaluating NT-300 (nitazoxanide extended-release tablets, 300 mg) versus placebo as a treatment for mild or moderate…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.